Biosimilars
Obtain critical industry information covering new biosimilars launches, information, company strategies, and new biosimilars product development.
Obtain critical industry information covering new biosimilars launches, information, company strategies, and new biosimilars product development.
52 Total results for product and free and sample content found
Datamonitor Healthcare: 医療用医薬品の市場調査レポート
It is important to understand how the biosimilar market has developed over the past five years. Take a look at some of the key events here.
Topic Biosimilars
Generics Bulletin: ジェネリック＆バイオシミラーニュース
Industry analysts from Generics Bulletin are bringing you free insights from their comprehensive biosimilars coverage. Obtain critical industry information covering new biosimilars launches, company strategies, and new biosimilars product development.
Topic biosimilars
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
For Scrip’s annual preview, our journalists asked over 80 industry executives and experts for their predictions of the major trends for 2020. From AI to M&A, gene therapy to the upcoming US election, here’s what to watch for as we begin this new decade.
Topic biosimilars biopharmaceutical
Generics Bulletin: ジェネリック＆バイオシミラーニュース
Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.
Topic Biosimilars Deal trends
Generics Bulletin: ジェネリック＆バイオシミラーニュース
Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.
Pink Sheet: 世界の薬事規制と承認審査に関するニュース
Bill addresses ‘dead zone’ for pending applications for protein products transitioning to biologic status; generic and brand industries each win in different legislative provisions: inclusion of the CREATES Act, and a revised definition for ‘biologics’ that includes chemically synthesized polypeptides.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
Aurobindo has taken home the awards for Company of the Year and Acquisition of the Year at the Global Generics & Biosimilars Awards 2019, held in Frankfurt, Germany. Accord also received two awards, among a host of other recognized companies.
Topic biosimilars
Generics Bulletin: ジェネリック＆バイオシミラーニュース
Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.
Topic biosimilars strategy
No Records Found
製品説明＆デモお申込
専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。
＊一部のサービスでは無料トライアルをご利用になれません。
お問い合わせ先
ご質問等ございましたらお気軽にご連絡下さい。
日本（平日：9時～18時）
電話：+81 (0)3 6273 4260
Email：inquiry.jp@informa.com
レポートストア
オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。
お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。